Wells Pharma of Houston LLC has recalled approximately 25,265 units of several injectable drug products, including Phenylephrine, Fentanyl Citrate, and Ketamine Hydrochloride. The recall was initiated due to deviations from Current Good Manufacturing Practice (cGMP) quality standards, which may affect the safety and effectiveness of the sterile solutions. These products were distributed nationwide to hospitals, infusion centers, and wholesalers between April 2026 and June 2026.
Sterile injectable solutions manufactured under substandard conditions may pose a risk of infection or unpredictable drug performance. While no injuries have been reported to date, these quality deviations mean the products may not meet safety and purity requirements.
Quantity Distributed: 13,070 IV Bags
Quantity Distributed: 4,030 IV Bags
Quantity Distributed: 2,940 IV Bags
Quantity Distributed: 50 syringes
Quantity Distributed: 150 syringes
Quantity Distributed: 4,975 syringes
Quantity Distributed: 50 syringes
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.